First AD

Second AD

Dato-DXd for Treating Advanced NSCLC

Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Insights Video Series

Year in Review: Updates in Antibody-Drug Conjugates for Treating Advanced NSCLC

Dr. Shirish Gadgeel discusses recent EVOKE-2 trial results showing promising response rates with sacituzumab govitecan combined with pembrolizumab for metastatic non-small cell lung cancer.

Sacituzumab Govitecan + Pembrolizumab in First-Line Metastatic NSCLC

Molecular Testing in Advanced NSCLC

T-DXd in HER2 Mutated Advanced NSCLC

Patritumab Deruxtecan (HER3-DXd) in Patients with EGFR Mutation-Positive Advanced NSCLC

Future Perspectives in ADCs for Treating Advanced NSCLC

Tackling All Questions ADC: How These Agents Are Joining a Treatment Revolution in NSCLC

Increasingly Targeted ADCs Drive NSCLC Treatment Innovations